Literature DB >> 29370679

Fecal calprotectin: beyond intestinal organic diseases.

Gian P Caviglia1, Davide G Ribaldone2, Chiara Rosso2, Giorgio M Saracco2,3, Marco Astegiano3, Rinaldo Pellicano3.   

Abstract

Fecal calprotectin (FC) is a calcium-binding protein with antimicrobic, imunomodulatory and antiproliferative properties that is mainly found in the cytoplasm of neutrophil granulocytes. During the last decades, FC became an increasingly useful tool both for gastroenterologists and for general practitioners for distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome. FC correlates with clinical scoring systems and endoscopic lesions in IBD and is considered a reliable biomarker for the prediction of clinical relapse or remission. However, FC elevation could be observed also in other gastrointestinal pathological conditions including infective colitis, microscopic colitis, eosinophilic colitis, adenomas and colorectal cancer. In addition, there are several non-pathological conditions that can lead to altered FC values. In this review, we aimed to point out individual, environmental and method-related factors that can affect FC measurement and thus its clinical interpretation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29370679     DOI: 10.23736/S0031-0808.18.03405-5

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  8 in total

1.  How to manage chronic diarrhoea in the elderly?

Authors:  Benjamin Crooks; Jimmy K Limdi; John McLaughlin
Journal:  Frontline Gastroenterol       Date:  2019-04-29

Review 2.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

3.  Inflammation in gastrointestinal disorders: prevalent socioeconomic factors.

Authors:  Davide Giuseppe Ribaldone; Rinaldo Pellicano; Giovanni Clemente Actis
Journal:  Clin Exp Gastroenterol       Date:  2019-07-19

4.  The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study.

Authors:  Marta Vernero; Federico De Blasio; Davide Giuseppe Ribaldone; Elisabetta Bugianesi; Rinaldo Pellicano; Giorgio Maria Saracco; Marco Astegiano; Gian Paolo Caviglia
Journal:  J Clin Med       Date:  2020-12-04       Impact factor: 4.241

5.  Predictive value of fibrinogen in identifying inflammatory bowel disease in active stage.

Authors:  Xiao-Fu Chen; Yuan Zhao; Yu Guo; Zhi-Ming Huang; Xie-Lin Huang
Journal:  BMC Gastroenterol       Date:  2021-12-15       Impact factor: 3.067

Review 6.  Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking.

Authors:  Ioana-Miruna Balmus; Ovidiu Ilie-Dumitru; Alin Ciobica; Roxana-Oana Cojocariu; Carol Stanciu; Anca Trifan; Mirela Cimpeanu; Cristian Cimpeanu; Lucian Gorgan
Journal:  Medicina (Kaunas)       Date:  2020-01-19       Impact factor: 2.430

7.  Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases.

Authors:  Lorenzo Bertani; Gian Paolo Caviglia; Luca Antonioli; Rinaldo Pellicano; Sharmila Fagoonee; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Corrado Blandizzi; Francesco Costa; Davide Giuseppe Ribaldone
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

Review 8.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.